Medical Expert Perspectives
Learn what medical experts have to say about PLUVICTO
Prostate Cancer & PLUVICTO Overview
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they discuss PLUVICTO, a treatment option for patients with PSMA+ mCRPC.
VISION Efficacy and Safety
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they review the results of the VISION trial.
PLUVICTO Dosing & Administration
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they dive into the dosing and administration of PLUVICTO.
Prostate Cancer, PSMA, and PLUVICTO
Watch Neal Shore, MD, FACS, provide an overview of the role of PSMA-PET, and the targeted therapy PLUVICTO, in mCRPC.
Prostate Cancer, PSMA, and PLUVICTO
Join Mark Fleming, MD, in discussing PSMA-PET imaging and PLUVICTO, including its mechanism of action in the mCRPC space.
VISION Study Design
Watch Mark Fleming, MD, provide an overview of the study design for VISION, a trial assessing PLUVICTO in patients with mCRPC.
VISION Study Design
Join Neal Shore, MD, FACS, as he walks you through the VISION trial study design.
PLUVICTO Patient Identification
Neal Shore, MD, FACS, discusses which types of patients may be eligible for PLUVICTO based on the VISION trial.
PLUVICTO Patient Identification
Mark Fleming, MD, reviews the patient population in the VISION trial and discusses which types of patients may be eligible for PLUVICTO.
Newsletter
PLUVICTO Spotlight: The VISION Study
The first in a series of newsletters covering topics important to HCPs considering PLUVICTO for their patients.
FACS, Fellow of the American College of Surgeons; mCRPC, metastatic castration-resistant prostate cancer; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.